Despite abundant genomic alterations in UASCC that are shared with other tumor types for which targeted therapies have been successfully developed, Cetuximab, an anti-EGFR antibody, remains the only approved gene-targeting drug for UASCC. Here, EGFR is linked to neoplasm.